All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins, pathogens and certain trafficking cells. Among these harmful substances are deleterious factors associated with aging, which can prematurely damage different tissues. The big question is what are those factors that mediate such effects, and what can be done to prevent them. The 11th Cardiac Regeneration and Vascular Biology Conference, held on the Island of San Servolo, Venice, from June 30 to July 2, 2025, included presentations, oral sessions and posters addressing the impact of aging on the cardiovascular system. Read More
The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not all, of these agents cause mutations and premature aging of normal blood cells. Read More
Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma. Read More
Innocare Pharma Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of the B7-H3 targeted antibody-drug conjugate. Read More
A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment of glioblastoma (GBM), an aggressive and incurable form of primary brain cancer. Read More
Insparin is a protein isolated from human adenovirus Ad36 that induces cellular glucose uptake without impacting safety. A preclinical study of insparin looked at its potential antidiabetic effects compared to those of pioglitazone. Read More
Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep disorders. Read More
Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting moiety acting as IKZF1 degradation inducers potentially useful for the treatment of cancer, autoimmune disease, neurodegeneration and inflammatory disorders. Read More
The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner mitochondrial membrane, and recent studies have linked some variants to mitochondrial encephalopathy. However, the exact disease mechanism and causal link remain unclear. Read More
Humanwell Healthcare (Group) Co. Ltd. has divulged Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of pain, autoimmune disease and dermatological disorders. Read More
Chinese investigators have published data from studies investigating CYT-997 for the treatment of hypertrophic scars. CYT-997 is a tubulin polymerization inhibitor that reached phase II clinical development for the treatment of multiple myeloma and glioblastoma multiforme. Read More
Additional early-stage research and drug discovery news in brief, from: Alpha Cognition, Audiocure Pharma, Inflectis Bioscience, Inventiva, Mira Pharmaceuticals. Read More
